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Smoking is a risk factor for developing chronic obstructive pulmonary disease (COPD), but there are no good
indicators for early identification of subjects who will develop symptomatic COPD. The aim of this study was to
investigate inflammatory mechanisms related to changes in lung function and emphysematous changes on high
resolution computed tomography (HRCT) in ‘healthy’ smokers. Subjects were 60-year-old men from a population
study. Bronchoscopy was performed in 30 smokers and 18 who had never smoked. Blood tests, lung function
measurements and HRCT were carried out in 58 and 34 subjects, respectively.
In comparison with never-smokers, smokers had higher levels of myeloperoxidase (MPO), human neutrophil
lipocalin (HNL), eosinophil cationic protein (ECP) and lysozyme in blood, higher levels of MPO, interleukin-8 (IL-
8) and HNL in bronchial lavage (BL), and of IL-8, HNL and interleukin-1b (IL-1b) in bronchoalveolar lavage
(BAL). Smokers also had lower levels of Clara cell protein 16 (CC-16) in blood. HNL in BL and BAL showed
strong correlations to other inflammatory markers (MPO, IL-8, IL-1b). The variations in MPO in BL were
explained by variations in HNL (R2=0?69), while these variations in BAL were explained by variations in HNL
and IL-1b (R2=0?76). DLCO was the lung function variable most closely related to MPO and IL-8 in BL and BAL
and to IL-1b in BAL. In a multiple regression analysis, MPO, IL-1b, IL-8 and CC-16 in BL and MPO in BAL
contributed to the explanation of variations in DLCO to 41% and 22%, respectively, independent of smoking
habits. In smokers with emphysematous lesions on HRCT, HNL in BAL correlated to emphysema score (rs=0?71).
We conclude that ‘healthy’ smoking men with a near normal FEV1 show signs of inflammation in the lower
airways that are related to a decrease in DLCO and to emphysematous lesions on HRCT. This inflammation seems
to be the result of both monocyte/macrophage and neutrophil activation.
Key words: smoking; inflammation; chronic obstructive pulmonary disease; bronchoalveolar lavage; cytokines;
computed tomography; lung function.
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Smoking-induced chronic obstructive pulmonary disease
(COPD) is common in the industrialized part of the world
and causes high morbidity and increasing mortality (1).
About 50% of all smokers develop chronic bronchitis and
at least 15% develop COPD (2). By the time the COPDReceived 25 January 2001 and accepted 26 January 2001.
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0954-6111/01/050363+11 $35?00/0patient seeks medical attention, the lung function is often
seriously deteriorated and the subject already severely
handicapped. At present, there are no good indicators to
enable early identification of subjects who will later develop
symptomatic COPD, except for the knowledge that
smoking is a risk factor.
The slope of phase III N2 test and DLCO have been
advocated to show early airway changes in smokers (3–5).
There are indications that histologic changes in the small
airways are related to lung function test thought to reflect
small airways (6). Smokers with chronic bronchitis have
increased numbers of neutrophils in fluids from the lower
airways, and also of various neutrophil associated# 2001 HARCOURT PUBLISHERS LTD
364 A. EKBERG-JANSSON ET AL.activation markers such as MPO and IL-8 (7–11). However,
in the early phase of COPD, the influence of cellular
inflammation and soluble inflammatory markers has not
been thoroughly studied. Knowledge on the relation
between the inflammatory markers and lung function
impairment in the early phase of disease is also poor.
In this study we recruited both smoking and never-
smoking subjects from a population study of 60-year-old
men who had never sought medical attention for airway
disease (‘healthy’). Among the smokers, we expected to find
subjects with slightly impaired lung function considered to
be mild COPD or a preclinical phase of the development of
COPD as described by Cherniack (12). Many of these
subjects were shown in an earlier study to have emphyse-
matous changes on high resolution computed tomography
(HRCT) (13). The aim was to study inflammatory
mechanisms related to changes in lung function i.e. forced
expiratory volume in 1 sec (FEV1), the slope of phase III
N2-test (N2 test) and DLCO, and to emphysematous
changes on HRCT in healthy smokers.
For this purpose we measured markers of neutrophils,
monocytes/macrophages and Clara cells in bronchial fluids
and in blood. Human neutrophil lipocalin (HNL) was
measured as a specific marker of neutrophils (14), while
measurement of myeloperoxidase (MPO) was considered to
reflect both neutrophils and monocytes/macrophages
(15,16). Lysozyme measurements in blood served as a
marker of monocytes/macrophages and in bronchial fluids
as a marker of the secretory activity of glands (17).
Interleukin 1b (IL-1b) served as a marker of macrophage
activity in bronchial fluids (18) together with the measure-
ment of interleukin-8 (IL-8) (19), although both these
cytokines may originate from other sources as well. Finally,
we measured the Clara cell protein (CC-16) in blood and
bronchial fluids as an indicator of the activity of the these
cells (20).
Materials and methods
SUBJECTS
The subjects were recruited from the population study ‘men
born in 1933 in Go¨teborg’, a random half of all men born in
1933 and residing in Go¨teborg in 1983 (n=1016) (21). In
1993, 879 men of the original cohort who were still alive
and living in Go¨teborg were recruited for a second
examination. Of the 602 participating men, 532 were
evaluated by spirometry. Of these men, 112 were smokers,
198 were never-smokers and 222 were former smokers who
had not smoked for 1 month. All smokers and a random
sample of 60 lifelong never-smokers were invited to
undergo a lung examination.
Fifty-eight smokers and 34 never-smokers consented to
further investigations and, of these, 30 smoking and 18
never-smoking men accepted to undergo a bronchoscopy.
Smoking habits were designated as 0=never-smokers,
1=1–515 cigarettes day71, 2=15 cigarettes day71.
Thirty-three of 58 (57%) were current heavy smokers
(15 cigarettes day71) and 25/58 (43%) were current lightsmokers (515 cigarettes day71). The median number of
pack-years was 35 (9–79) years.
Among the subjects originally included in the study,
subjects were excluded if they (i) had any airway disease for
which they had sought medical attention (n=11), (ii) had a
history of congestive heart failure or unstable angina
pectoris (n=4), or (iii) had any other severe disease
(n=5). Subjects would also have been excluded if they
had (iv) scoliosis or other diseases with deformation of
thorax, (v) any kind of infection during the 4 weeks
preceding the examination, or (vi) if they were on treatment
with corticosteroids, N-acetylcysteine (NAC) or acetylsa-
licylic acid (ASA) less than 4 weeks prior to blood tests or
bronchoscopy. No subject was excluded according to iv–vi.
ASA treatment was allowed in subjects with prior heart
infarction (n=8). Four smokers had quit smoking before
they came to the follow-up and were therefore excluded.
The rest of the drop-outs were not willing to take part in the
study for various reasons (n=56). The drop-out frequency
was equally distributed in smokers and never-smokers.
The study was approved by the local Ethics Commite´e at
Sahlgrenska University Hospital, Go¨teborg, Sweden.
FIBREOPTIC BRONCHOSCOPY AND
SAMPLE COLLECTIONS
The subjects were examined in the supine position.
Bronchoscopies were performed by one experienced
bronchoscopist between 08?00 and 10?00 hours. Premedica-
tion was given with 5 mg diazepam orally and 0?5 ml
morphine–scopolamin intra-muscularly. In case of kidney
or gall bladder disease petidine 75 mg intra-muscularly and
atropine 0?5 mg subcutaneously were given. Additional
diazepam (2?5–5?0 mg) intravenousely could also be given.
All persons were given nebulized terbutalin 0?25 mg dose71
263 before bronchoscopy. Local anaesthesia was given
initially with 1% tetracaine spray in the mouth and
laryngeal tract. Additional anaesthesia for the lower
respiratory tract was given via the bronchoscope (Olym-
pus). Oxygen saturation was measured during the broncho-
scopy, and the subjects were given supplemental oxygen
(2–3 lmin71) via a nasal catheter.
Bronchoalveolar lavage was made as a fractionated small
volume lavage 10 ml3650 ml of sterile and endotoxin-
free phosphate buffered saline (PBS). The first 10 ml were
processed separately as bronchial lavage (BL). The
remainder, the bronchoalveolar lavage (BAL), were pooled
into a sterile siliconized bottle and transportated on ice
immediately to the laboratory. At the laboratory the total
volume of the lavage was measured and centrifuged at 250 g
and 48C for 10 min. The supernatant was centrifuged a
second time at 10 000 g and frozen at 7708C for later
analysis of soluble inflammatory markers.
The total cell number was determined using a haemo-
cytometer. Cell viability was estimated using tryptan blue
exclusion. Calculation of cell differentials was done on
cytocentrifuged preparations (Cytospin 2; Shandon South-
ern Products LTD, Runcorn, U.K.) stained with May–
Gru¨nwald–Giemsa counting 1000 cells.
INFLAMMATORY MARKERS AND EMPHYSEMATOUS CHANGES IN SMOKERS 365Blood samples for analysis of lymphocyte counts were
also taken.
ANALYSIS OF INFLAMMATORY MARKERS
Human neutrophil lipocalin (HNL) was determined in
serum and BL and BAL fluid using a solid phase double-
ligand fluoroimmunoassay (FEIA) (22). Briefly, HNL in
standard or sample was allowed to bind to an anti-HNL
mouse monoclonal antibody (mAb) coupled to Immuno-
CAP (Pharmacia & Upjohn, Diagnostic AB, Uppsala,
Sweden). After washing, b-galatosidase-labelled anti-HNL
mab was added and allowed to bind to the HNL. After a
final wash, the amount of HNL was determined by
fluorescence after adding 4-methylumbelliferyl-b-D-galac-
tosidase as enzyme substrate. HNL, purified from neutro-
phil granulocytes, was used as standard ranging from
20 mg l71 to 600 mg l71. The intra-assay and inter-assay
coecients of variation were less than 10%, and the
detection limit was 3 mg l71.
Clara cell protein 16 (CC-16) was determined in serum
and BL and BAL fluid using a solid phase double ligand
fluoroimmunoassay (FEIA) (23). Briefly, CC-16 in standard
or sample was allowed to bind to an anti-CC-16 mouse
mAb coupled to ImmunoCAP (Pharmacia & Upjohn).
After washing, b-galactosidase-labelled anti-CC-16 mAb
was added and allowed to bind to the CC-16. After a final
wash, the amount of CC-16 was determined by fluorescence
after adding 4-methylumberiferyl-b-D-galactosidase as en-
zyme substrate. CC-16, purified from human urine, was
used as standard ranging from 1 mg l71 to 100 mg l71. The
intra-assay and inter-assay coecients of variation were less
than 10%, and the detection limit was less than 1 mg l71.
Interleukin-8 (IL-8) was determined in serum and
bronchial lavage (BL) and BAL fluid using a solid phase
fluorescent enzyme immuno assay (24). Briefly, the BAL
fluid was incubated in micro-titre wells coated with a mouse
monoclonal antibody against IL-8. After washing, a goat
anti-IL-8 b-galactosidase conjugate was added and the
plates were incubated. The amount of IL-8 was measured
by adding 4-methylumbelliferyl-b-D-galactosidase as en-
zyme substrate. Recombinant IL-8 was used as standard,
ranging from 25 ng l71 to 1600 ng l71. The intra-assay and
inter-assay coecients of variation were less than 10%, and
the detection limit was 5 ng l71.
Lysozyme was titrated in serum and BL and BAL fluid
by incubating standard solution or samples with Sephadex-
bound anti-lysozyme for 2 h before an addition of 125I-
labelled lysozyme (25). Incubation was then continued for
20 h during rotation end-over-end. After washing four
times, the radioactivity of the pellet was determined in a
well-type scintillation counter. Lysozyme purified from
human blood was used as standard ranging from 3 mg l71
to 900 mg l71. The intra-assay and inter-assay coecients of
variation were less than 10%, and the detection limit was
less than 3 mg l71.
MPO and interleukin-1b (IL-1b; ultra-sensitive kit), were
determined in serum and BL and BAL (except for IL-1b
which was determined only in BL and BAL) by commer-cially available kits (Pharmacia & Upjohn Diagnostics AB
and Biosource International, Camarillo, CA, U.S.A.),
according to the instructions of the manufacturer.
LUNG FUNCTION TESTS
In all subjects lung volumes, spirometry, single breath N2
test and diffusion capacity test were determined. Lung
volumes were obtained by a flow displacement body
pletysmograph (Body Box 2800; SensorMedics Co., Biltho-
ven, The Netherlands). FEV1 and vital capacity (VC) were
obtained on a water-sealed regularly calibrated bell
spirometer. The slope of phase III was obtained by the
single breath N2 method (26). Carbon monoxide transfer
(DLCO) was assessed by the single breath method with
standard equipment (SensorMedics 2200; SensorMedics
Co.) We used the European Respiratory Society reference
values (27) for lung volumes and spirometry, and for the
single breath N2 test we used data from Sixt et al. (28). For
DLCO and carbon monoxide transfer factor (DLCO/VA) we
used the reference values according to Salorinne (29).
HIGH RESOLUTION COMPUTED
TOMOGRAPHY (HRCT)
The examination was performed with a Picker PQ 2000.
The subjects were examined in a supine position and in full
inspiration. The entire thorax was scanned with a slice
thickness of 1?5 mm and 3 cm inter-slice distance. Exposure
data were 130 kV and 200 mA. The images were recon-
structed with the sharp algorithm of Picker and six images
were copied to each 14@617@ film. Window width was set at
1400 HU and the level at 7400HU.
The images were analysed from the hard copies by two
experienced chest radiologists independently, without
knowledge of whether the subject was a smoker. The
radiologists analysed each slice in each lung. The diagnosis
of emphysematous changes was based on findings of areas
of low attenuation and/or presence of stretched, narrowed
vessels. The degree of emphysema was scored as 0=no
emphysema, 1=1–25% of the parenchymal area was
involved, 2=26–50% involvement, 3=51–75% involve-
ment and 4=more than 75%. The mean scores for the slices
obtained were calculated. In this way, a score of total lung
involvement could be calculated and the individual obser-
ver’s evaluations compared. The kappa value was 0?78.
All subjects were examined by HRCT. The technical
quality was insucient in one smoker and two never-
smokers so they were excluded. As demonstrated in an
earlier paper emphysematous changes were shown in 25/57
smokers (44%) and 1/32 (3%) never-smokers. In subjects
with emphysematous changes the mean values of the
emphysema score ranged from 0?09 to 1?63 (13).
STATISTICAL METHODS
Group data are presented with their mean and range. For
lung function variables mean and standard deviation (SD)
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comparison between smokers and never-smokers and for
the comparison of inflammatory markers between subjects
with and without HRCT lesions. The w2 test and Fischer’s
exact test were used for the comparison between categories.
The non-parametric Spearman rank correlation coecient
(rs) was used for correlation analyses between lung function
and inflammatory markers as well as between emphysema
score and inflammatory markers. A multi-variate stepwise
backward regression analysis was used. All tests were two-
sided, and P-values lower than 0?05 were regarded as
significant. We used Stat View 4?51 and Statistica1 for
Windows (Stat Soft) as the statistical packages.
Results
INFLAMMATORY CELLS RELATED TO
SMOKING
In bronchoalveolar lavage (BAL) the cell concentration
was higher in smokers as compared with never-smokers
(Table 1). However, the total number of cells in the BAL
fluid was similar in smokers and never-smokers. The
recovery of BAL fluid was lower in smokers. The
percentage of alveolar macrophages was higher and the
percentage of lymphocytes was lower in smokers than in
never-smokers, whereas the percentage of neutrophils did
not differ. Heavy or light smoking habits did not influence
these outcomes.
In bronchial lavage (BL), a higher percentage of
neutrophils but no differences concerning macrophages
and lymphocytes, were shown in smokers as compared withTABLE 1. Recovery and cell viability in BAL. Cell populations i
Smok
(n3
Total number of cells in BAL (6106) 15?2
Cell concentration in BAL (6104 cellsml71) 23?1
Recovery in BAL (ml) 64
Cell viability in BAL (alive/dead, %) 68
Cell differential counts — BAL (%)
Macrophages 93
Lymphocytes 1
Neutrophils 2
Eosinophils 0?4
Ciliated cells 2
Cell differential counts — bronchial lavage (%)
Macrophages 14
Lymphocytes 0?2
Neutrophils 40
Eosinophils 1
Ciliated cells 38
Data are given as mean (range).
*P according to the Mann–Whitney U-test; NS=not significannever-smokers (Table 2). The percentage of ciliated cells
was lower in smokers than in never-smokers. Heavy or light
smoking habits did not influence these outcomes.
INFLAMMATORY MARKERS RELATED TO
SMOKING
Human neutrophil lipocalin
Human neutrophil lipocalin (HNL) was higher in smokers
than in never-smokers in all compartments (BAL, bronchial
lavage and blood) (Table 2). Heavy or light smoking habits
did not influence these outcomes and there was no
correlation to pack-years.
In bronchial lavage and BAL, HNL correlated with the
percentage of neutrophils in bronchial lavage (Fig. 1) and
BAL (rs=0?37, P=0?01), respectively. Both in bronchial
lavage and in BAL HNL correlated to other inflammatory
markers (MPO, IL-8, IL-1b) associated to neutrophils
(Table 3). In blood, HNL strongly correlated to MPO
(rs=0.75, P50.0001) but not to IL-8, but the levels of IL-8
were low in blood. IL-1b in blood was not analysed.
Myeloperoxidase
In blood, myeloperoxidase (MPO) was higher in smokers
as compared to never-smokers. This was also true for
bronchial lavage but not bronchoalveolar lavage
(Table 2). MPO in blood was higher in heavy smokers
as compared with light smokers [270 (160–490) vs. 220
(120–470) mg l71, P=0.005]. There was no correlation to
pack-years.n BAL and bronchial lavage
ers
0)
Never-smokers
(n17)
P*
(0?5–48) 8?5 (0?2–18) NS
(1?2–68?5) 9?2 (2?5–20?0) 0?002
(30–110) 89 (50–120) 0?0003
(42–88) 74 (43–86) NS
(39–99) 87 (75–96) 50?0001
(0–5) 10 (0–23) 50?0001
(0–11) 2 (1–5) NS
(0–2) 0?8 (0–3) NS
(0–45) 0?2 (0–3) NS
(0–69) 17 (3–45) NS
(0–1) 0?1 (0–1) NS
(1–87) 19 (1–79) 0?01
(0–10) 0?4 (0–4) NS
(0–90) 58 (5–91) 0?03
t; n=number of subjects.
TABLE 2. Inflammatory markers in blood, bronchial lavage and bronchoalveolar lavage in smokers and never smokers
Blood Bronchial lavage Bronchoalveolar lavage
Smokers
(n=51)
Never-smokers
(n=32)
P* Smokers
(n=30)
Never-smokers
(n=17)
P* Smokers
(n=30)
Never-smokers
(n=17)
P*
HNL (mg l71) 168 (80–330) 139 (79–260) 0?02 154 (39–460) 69 (39–160) 0?02 85 (39–470) 54 (39–210) 0?05
MPO (mg l71) 251 (120–490) 198 (120–330) 50?001 39 (15–89) 20 (15–45) 0?01 21 (7–120) 11 (7–20) NS
IL-8 (ng l71) 17 (9–410) 9 (9–11) NS 75 (11–270) 39 (19–160) 0?01 73 (9–440) 21 (9–110) 0?0004
IL-1b (ng l71) — — — 0?9 (0–6) 0?4 (0–1) NS 4 (0–21) 0?4 (0–3) 0?0002
Lysozyme (mg l71) 1410 (790–2660) 1100 (810–1740) 0?01 980 (5–2250) 620 (120–1850) NS 530 (70–4970) 330 (80–930) NS
CC-16 (mg l71) 23 (8–69) 34 (17–70) 50?0001 2180 (1–5150) 2420 (350–5740) NS 960 (220–2240) 1240 (300–2680) NS
Data are given as mean (range).
*P according to the Mann–Whitney U-test; NS=not significant; n=number of subjects.
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TABLE 3. Univariate correlations between human neutrophil
lipocalin (HNL) in bronchial lavage and BAL and other
neutrophil associated inflammatory markers in the same
compartments
Bronchial lavage BAL
rs P* rs P*
MPO 0?59 50?0001 0?66 50?0001
IL-8 0?66 50?0001 0?85 50?0001
IL-1b 0?67 50?0001 0?67 50?0001
rs according to the Spearman rank correlation coecient.
*P-value of significance according to the Spearman rank
correlation test.
FIG. 1. Human neutrophil lipocalin (HNL) in bronchial lavage of smokers (*) and never-smokers (&) related to (a)
neutrophils (%), (b) myeloperoxidase (MPO), (c) interleukin-8 (IL-8) and (d) interleukin-1b (IL-1b) in the same
compartment (rs according to the Spearman rank correlation coecient, P-value of significance according to the Spearman
rank correlation test).
368 A. EKBERG-JANSSON ET AL.In all compartments (both blood and bronchial fluids) a
Spearman rank correlation test showed MPO to be
correlated to HNL (see above). In multiple regression
analysis that included HNL, IL-8 and IL-1b in the model,
the variations in MPO in BL were only explained by
variations in HNL (R2=0?69, P50?0001), whereas in BALthese variations were explained by variations in both HNL
and IL-1b (R2=0?76, P50?0001) (Table 4). This data
indicates that MPO in BL mainly reflects the activity of
neutrophils, whereas the levels of MPO in BAL reflect both
the variations in neutrophil and monocyte activities.
Other inflammatory markers
In the blood lower levels of CC-16 were found in smokers
as compared with that of never-smokers (Table 2), but the
levels were similar in bronchial fluids. In the blood there
was a correlation between CC-16 and pack-years
(r=70?30, P=0?04).
In bronchial fluids (BAL and BL) IL-8 showed higher
levels in smokers, but similar levels in blood (Table 2) as
compared to never-smokers. IL-1b was only measured in
bronchial fluids and showed significantly higher levels in
BAL in smokers. In the blood the lysozyme levels were
higher in smokers but were similar in bronchial fluids as
compared with never-smokers. In blood lysozyme level was
higher in heavy smokers as compared with light smokers
[1500 (790–2660) vs. 1270 (830–2030) mg l71, P=0?02] but
there was no correlation to pack-years .
TABLE 4. Stepwise multiple regression analysis (backwards) in smokers and never-smokers with MPO as the dependent
variable and HNL, IL-8 and IL-1b in bronchial lavage (BL) as the independent variables (n=47)
(a) MPO in bronchial lavage
R=0?83 R2=0?69 Adjusted R2=0?69 P50?0001 SE of estimate: 12?8
B SE of B P-level
Intercept 11?6 2?7 0?000
HNL BL 0?16 0?02 50?0001
(b) MPO in BAL
R=0?87 R2=0?76 Adjusted R2=0?75 P50?0001 SE of estimate: 11?1
B SE of B P-level
Intercept 3?1 2?4 0?000
HNL BAL 0?07 0?03 0?02
II-1b BAL 3?4 0?49 50?0001
R=regression coecient; B=the raw regression coecient.
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Lung function measurements were impaired in smokers
seen in FEV1, VC, DLCO, carbon monoxide transfer factor
(DLCO/VA ) and N2 test, as compared with never-smokers
(Table 5).
The influence of the degree of current smoking was only
significant between heavy and light smokers in total lung
capacity (TLC) [101% (SD 13%) vs. 93% (SD 12%),
P=0?02] and residual volume (RV) [124% (SD 30%) vs.
104% (SD 30%), P=0?01]. The influence of pack-years i.e.
when the smokers were divided into two groups under and
above the median pack-years (35), was only significant for
TLC [101% (SD 12%) vs. 94% (SD 13%), P=0?04].
INFLAMMATORY MARKERS RELATED TO
LUNG FUNCTION TESTS
Among smokers the Spearman rank correlation test showed
correlations between MPO in bronchial fluids and DLCO
(Fig. 2) but not between MPO and FEV1 or the results of
the N2 test. DLCO showed a negative correlation to IL-1b
in BAL (rs=70?48, P=0?007) and to IL-8 in BL and
BAL (rs=70?37, P=0?03 and rs=70?42, P=0?02,
respectively).
Multiple regression analysis that included all markers in
the model and smoking habits showed that MPO, IL-1b,
IL-8 and CC-16 in BL as independent variables contributed
to the explanation of 41% (P50?0003) of the variations in
DLCO (Table 6). The contribution of IL-8 and CC-16 was
small, however. A similar estimation with the results in
BAL showed that MPO as the only independent variableexplained 22% of the variations in DLCO (P50?0009).
When MPO was removed from the analysis, it was seen that
HNL in BL and HNL and IL-1b in BAL to a certain extent
replaced MPO as an independent explanatory variable.
None of the blood variables offered any explanation to
the variations in DLCO, either by means of an univariate
analysis or in a multiple regression analysis when smoke
habit was included in the model.
INFLAMMATORY CELLS AND MARKERS
RELATED TO EMPHYSEMATOUS
CHANGES
Inflammatory cells and emphysematous changes
In BAL, the cell concentration and the total number of
cells in the BAL fluid were higher in smokers with
emphysematous lesions as compared with smokers with-
out lesions [31?0 (7?7–68?6) vs. 16?9 (1?2–43?6)6104
cellsml71, P=0?02] and [20?0 (4?5–48?0) vs. 10?8
(0?5–25?0)6106 cells, P=0?05]. The number of alveolar
macrophages in BAL was also higher in smokers
with emphysematous lesions as compared with smokers
without lesions [29?5 (7?5–65?1) vs. 16?0 (0?5–40?6)6104
cellsml71, P=0?03]. There was no difference concer-
ning cell recovery, cell viability, lymphocytes, neutro-
phils, eosinophils and ciliated cells in BAL between the
groups.
In bronchial lavage, there was no significant difference
concerning percentage of macrophages, neutrophils, lym-
phocytes, eosinophils and ciliated cells in smokers with
370 A. EKBERG-JANSSON ET AL.emphysematous lesions as compared with smokers without
lesions.
Inflammatory markers and emphysematous
changes
In the blood, we found HNL and MPO to be higher in
smokers with emphysematous lesions as compared with
smokers without lesions [190 (100–300) vs. 150 (80–
330)mg l71, P=0?01] and [280 (190–470) vs. 230 (120–
490)mg l71, P=0?01]. CC-16 was found to be lower in the
blood of smokers with emphysematous lesions [20 (8–44) vs.
25 (11–69), P=0?02]. There was no difference in BAL or
bronchial lavage between the groups. However, in BAL of
smokers with emphysematous changes HNL but neither MPO
nor CC-16 correlated to emphysema score (rs=0?71, P=0?01)
(Fig. 3). This was not seen in bronchial lavage or blood.
IL-8, IL-1b and lysozyme were similar in blood, BAL
and BL in smokers with emphysematous lesions and
smokers without lesions.FIG. 2. DLCO related to myeloperoxidase (MPO) in (a) bronchi
Spearman rank correlation coecient, P-value of significance a
TABLE 5. Lung function tests
Smokers
(n=58)
Never-
smokers
(n=34)
P*
TLC (% pred.) 97+12 97+11 NS
RV (% pred.) 115+31 102+28 NS
VC (% pred.) 88+13 94+12 0?05
FEV1 (% pred.) 94+17 109+14 50?0001
N2-test (% pred.) 188+84 92+40 50?0001
DLCO (% pred.) 82+15 97+14 50?0001
DLCO/VA (% pred.) 82+16 94+12 50?001
Data are given as mean (+SD).
*P according to the Mann–Whitney U-test; NS=not
significant; n=number of subjects.Discussion
This study aimed to evaluate inflammation in a mild
phase of COPD. Our study group was ‘healthy’ smoking
and never-smoking men around 60 years of age recruited
from a population study in Go¨teborg. We hypothesized
that, in a cohort of ‘healthy smokers’, there will be
individuals with preclinical COPD (12). Our aim was to
study the inflamma-tion and the soluble inflammatory
markers in subjects with only mild lung function impair-
ment (preclinical disease).
The 60-year-old smokers that we investigated were
selected in the sense that subjects with symptomatic
(clinical) COPD were excluded. These selected subjects will
most probably never develop severe COPD as they have
already been shown to be ‘resistant’ to tobacco smoke to
some extent. Hence, the mean FEV1 in our smokers was
only slightly decreased while the N2-test and DLCO were
more affected as compared with both predicted values and
with never-smokers in the present study (Table 5).
However, our earlier findings of subclinical emphysema in
these subjects further support some of these subjects to be
in a preclinical phase of COPD (13).
It is well established that smoking induces a cellular
inflammation in the airways with a preponderance of
neutrophils (7). In the present study, smokers showed an
increased percentage of neutrophils in bronchial lavage but
not in BAL fluid. However, soluble inflammatory markers,
both in blood, bronchial lavage and BAL, clearly indicated
a neutrophil inflammation in smokers as compared with
never-smokers. The neutrophil granule proteins, HNL and
MPO, are released from the neutrophils upon activation
(14,17,30). HNL and lactoferrin originate from the same
class of granule and it is released early and easily
(31–33). This might explain why HNL was the only
marker of neutrophil inflammation showing increased
levels both in the blood and in the bronchial fluids
(bronchial lavage and BAL).
Our data confirm earlier findings of increased levels of
MPO in asymptomatic smokers (8) and a correlational lavage and (b) BAL in smokers (rs according to the
ccording to the Spearman rank correlation test).
TABLE 6. Stepwise multiple regression analysis (backwards) in smokers and never-smokers with DLCO (% pred.) as the
dependent variable and HNL, MPO, IL-8, IL-1 b, Lys, CC-16 and smoking habits as the independent variables (n=47).
(a) Bronchial lavage
R=0?64 R2=0?41 Adjusted R2=0?35 P50?0003 SE of estimate: 13?4
B SE of B P-level
Intercept 97?9 4?2 0?000
MPO BL 70?52 0?13 0?0002
IL-1b BL 9?9 3?3 0?005
IL-8 BL 70?13 0?001 0?04
CC-16 BL 0?00004 0?00001 0?01
(b) BAL
R=0?47 R2=0?22 Adjusted R2=0?20 P50?0009 SE of estimate: 15?0
B SE of B P-level
Intercept 94?1 2?8 0?000
MPO BAL 70?36 0?10 0?009
R=regression coecient; B=raw regression coecient.
FIG. 3. Emphysema score and human neutrophil lipocalin
(HNL) in smokers (rs according to the Spearman rank
correlation coecient, P-value of significance according
to the Spearman rank correlation test).
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(9,10,34–36). In this study, we extended the armamentar-
ium of neutrophil activation markers with HNL, earlier
used in some airway studies of COPD (37,38), in healthy
smokers (39) and in one study of cystic fibrosis (33). Our
study shows increased levels of this marker in smokers.
HNL also correlate to MPO and to IL-8 and to the pro-
inflammatory cytokine IL-1b. Thus, in asymptomatic
smokers, HNL is a valid marker of neutrophil activation
and has the potential to be more specific for neutrophilic
activation than MPO, as MPO may also reflect monocyte
activation (16).CC-16 in blood was lower in smokers as compared to
never-smokers. CC-16 is the major secretory protein from
the Clara cells of the respiratory tract, where it acts as a
downregulator and protects the respiratory tract from
exaggerated inflammatory reactions. The level of CC-16 is
thought to be a sensitive marker of non-ciliated bronchial
cell dysfunction. Low levels of CC-16 in blood in smokers
have been described earlier (40). Bernard et al. also found
low levels of CC-16 in BAL in COPD patients (20). The
smokers in our study had only mild signs of airway
obstruction, which might explain why we did not find lower
local levels of CC-16 in our smokers as compared with the
never-smokers. Possibly, the relatively high level of CC-16
in the airways could explain why these subjects did not
develop more severe COPD.
We found elevated levels of lysozyme in the blood of
smokers as well as locally elevated levels of IL-1b and IL-8,
i.e. in bronchial lavage and bronchoalveolar lavage. These
inflammatory markers reflect monocyte/macrophage acti-
vation (41,42) and the factors are involved in the recruit-
ment of neutrophils (17,43). IL-8 is also an activator of
neutrophils (19).
One important objective of this study was to evaluate the
relations between pulmonary function and markers of
cellular activity in smokers. In the present material only
DLCO correlated to inflammatory markers. This may
indicate that DLCO is a more sensitive indicator of
preclinical COPD than FEV1, in accordance with earlier
results indicating that impairment of DLCO is an early sign
of smokers induced airway disease (5,44). However, this
might not necessarily be true in a more advanced disease
stage. In these subjects we have earlier shown a correlation
372 A. EKBERG-JANSSON ET AL.between CD8+ lymphocytes in central bronchial biopsies
and FEV1 (45). This may indicate that FEV1 in a preclinical
disease stage mainly reflects more central airway events and
to a lesser extent more peripheral events. This last statement
gets further support by a recent paper con-cerning the same
population where we have shown that men with mild
respiratory symptoms had lower FEV1, while no association
could be seen between symptoms and DLCO (46).
In the multiple regression analyses, MPO in both BL
and BAL was the most important contributing variable
to explain the variation in DLCO, even when smoking
habits were taken into account. The finding that HNL,
especially in BL, replaces MPO in the multiple regression
analysis indicates that neutrophils are important in the
development of impaired DLCO. The finding in BAL that
IL-1b also replaces MPO in the multiple regression analysis
also suggests that monocytes (together with neutrophils)
are involved in the development of decreased DLCO in
the more peripheral segments of the airways. This concept
is also strengthened by the correlations seen in multiple
regression analyses in this study between MPO and
HNL on the BL level and HNL together with IL-1b on
the BAL level.
This study also extends its focus from lung function
variables to emphysematous changes seen on HRCT. There
seem to be parallel changes in HRCT and DLCO in this
preclinical phase of COPD, as well as cellular changes with
increased percentages of neutrophils and monocytes/
macrophages in the peripheral airway segments studied by
BAL fluid. Furthermore, the most specific neutrophil
activation marker, HNL, correlates to the extent of
emphysema in the smokers. This indicates that, within the
smoking population, the neutrophilic activation is strongly
related to the degree of emphysema. There is also a relation
between neutrophil activation markers and a fall in DLCO
studied with multiple regression analysis, where smoking
habits was one of the independent variables.
In conclusion, this study shows that smokers without
known airway disease do show several signs of airway
inflammation and lung function deterioration. Markers of
neutrophil and monocyte/macrophage activation correlate
to lung function deterioration and early emphysematous
changes, independently of smoking habits, which indicates
that this could be a primary event in smoking induced
airway inflammation. These activation mechanisms are
possibly different in smokers who develop COPD and in
smokers who do not develop COPD. The peripheral
inflammatory events seem to be best reflected physiologi-
cally in DLCO measurements.
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